NINGBO MENOVO PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.8 CNY | +3.84% |
|
+8.07% | -27.82% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,696 | 5,555 | 5,312 | 5,494 | 4,080 | 2,944 | - |
| Enterprise Value (EV) 1 | 3,696 | 5,555 | 5,312 | 5,494 | 4,080 | 2,944 | 2,944 |
| P/E ratio | 24 x | 32.9 x | 38.6 x | 17.3 x | 382 x | 12.9 x | 9.72 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.13 x | 4.65 x | 4.22 x | 3.77 x | 3.35 x | 1.69 x | 1.4 x |
| EV / Revenue | 3.13 x | 4.65 x | 4.22 x | 3.77 x | 3.35 x | 1.69 x | 1.4 x |
| EV / EBITDA | 14.5 x | 17.2 x | 18.2 x | 10.7 x | 29.1 x | 6.66 x | 5.69 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | 2.71 x | 3.58 x | 3.2 x | 2.72 x | 2.01 x | 1.22 x | 1.1 x |
| Nbr of stocks (in thousands) | 209,109 | 209,007 | 208,979 | 213,378 | 213,407 | 213,351 | - |
| Reference price 2 | 17.67 | 26.58 | 25.42 | 25.75 | 19.12 | 13.80 | 13.80 |
| Announcement Date | 4/20/20 | 4/19/21 | 4/25/22 | 4/3/23 | 4/29/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,180 | 1,194 | 1,258 | 1,457 | 1,216 | 1,745 | 2,100 |
| EBITDA 1 | 254.3 | 323.2 | 291.7 | 514.6 | 140 | 442 | 517.4 |
| EBIT 1 | 189.7 | 215.5 | 187.9 | 405.3 | 18.75 | 282.8 | 366.2 |
| Operating Margin | 16.08% | 18.06% | 14.94% | 27.82% | 1.54% | 16.21% | 17.44% |
| Earnings before Tax (EBT) 1 | 187.2 | 214.7 | 180.3 | 384.2 | 7.958 | 264 | 346.1 |
| Net income 1 | 150.9 | 167.4 | 142.5 | 338.7 | 11.59 | 229.3 | 303.4 |
| Net margin | 12.79% | 14.02% | 11.33% | 23.25% | 0.95% | 13.14% | 14.45% |
| EPS 2 | 0.7373 | 0.8089 | 0.6585 | 1.490 | 0.0500 | 1.070 | 1.420 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/20/20 | 4/19/21 | 4/25/22 | 4/3/23 | 4/29/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 11.9% | 11.5% | 8.54% | 17.6% | 0.56% | 9.5% | 11.3% |
| ROA (Net income/ Total Assets) | - | 5.9% | - | - | - | - | - |
| Assets 1 | - | 2,838 | - | - | - | - | - |
| Book Value Per Share 2 | 6.520 | 7.420 | 7.940 | 9.450 | 9.510 | 11.30 | 12.60 |
| Cash Flow per Share 2 | 0.8600 | 1.200 | 1.040 | 1.300 | 0.0400 | 0.9600 | 1.300 |
| Capex 1 | 325 | 311 | 528 | 568 | 219 | - | - |
| Capex / Sales | 27.57% | 26.07% | 41.95% | 39% | 18.03% | - | - |
| Announcement Date | 4/20/20 | 4/19/21 | 4/25/22 | 4/3/23 | 4/29/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
13.8
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.82% | 407M | |
| +26.08% | 662B | |
| +21.13% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 289B | |
| +13.68% | 234B | |
| +4.61% | 198B | |
| -10.55% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- 603538 Stock
- Financials Ningbo Menovo Pharmaceutical Co., Ltd.